Safeguard Your IP

July 24, 2015

Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.

Jennifer Collins recently wrote an article that was featured in BioPham International. Read the full article here on BioPharmInternational.com

 

castle-838353_1920

Return to News & Content